ClearGuard HD
Commercial- Indications
- Catheter-related bloodstream infections, Hemodialysis catheter infections
Company intelligence / Profile preview
The company's lead product, ClearGuard HD Antimicrobial Barrier Cap, was the first and only device available for sale in the US proven to reduce central line-associated bloodstream infections in hemodialysis patients. It received CE Mark approval and Medical Device Single Audit Program certification for international markets in 2019[1][2][3]. No clinical trial pipeline as typical for drug companies; commercialized medical device with demonstrated efficacy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pursuit Vascular.